Next-Generation Necrotic Enteritis Vaccine System

Publication ID: 24-11857613_0005_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Next-Generation Necrotic Enteritis Vaccine System,” Published Technical Disclosure No. 24-11857613_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857613_0005_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,613.

Summary of the Inventive Concept

A pioneering vaccine system for necrotic enteritis in poultry, leveraging plant-based expression, nanocapsule delivery, and AI-driven development to provide unparalleled protection against C. perfringens infection.

Background and Problem Solved

The original patent's vaccine composition, while effective, has limitations in terms of production scalability, delivery efficiency, and adaptability to emerging strains. This new inventive concept addresses these limitations by introducing a novel, plant-based expression system for producing fusion proteins, a slow-release nanocapsule delivery system, and AI-driven development to accelerate vaccine development and enhance efficacy.

Detailed Description of the Inventive Concept

The new inventive concept comprises a plant-based expression system engineered to produce a PlcC-NetB fusion protein, which is then administered to poultry in a slow-release, nanocapsule-based delivery system. This system enables prolonged protection against C. perfringens infection. Additionally, the inventive concept incorporates an AI-driven development platform to identify optimal antigen combinations and adjuvants, thereby accelerating the development of effective vaccines. The system also includes a wearable device for monitoring the bird's health status, coupled with a machine learning algorithm to predict the likelihood of C. perfringens infection, enabling early intervention and prevention.

Novelty and Inventive Step

The new claims introduce a paradigm shift in necrotic enteritis vaccine development by integrating plant-based expression, nanocapsule delivery, and AI-driven development. These novel elements provide a significant improvement over the original patent's composition, offering enhanced efficacy, scalability, and adaptability.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different plant-based expression systems, varying the composition of the nanocapsule delivery system, or incorporating additional AI-driven tools for vaccine development and monitoring. These variations would ensure broad conceptual coverage and adaptability to diverse poultry production settings.

Potential Commercial Applications and Market

The next-generation necrotic enteritis vaccine system has significant commercial potential in the poultry industry, with potential applications in vaccine development, production, and distribution. The target market includes poultry farmers, vaccine manufacturers, and animal health companies seeking to improve bird health and reduce mortality rates.

CPC Classifications

Section	Class	Group
A	A61	A61K39/08
A	A61	A61P31/04
C	C12	C12N15/74
C	C12	C12N15/8258
A	A61	A61K2039/552
A	A61	A61K2039/55577

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Veterinary biotechnology, specifically vaccine development for poultry diseases, involving protein engineering, expression systems, and immunological interventions

Person of Ordinary Skill (PHOSITA) Profile

A researcher with expertise in molecular biology, protein engineering, veterinary immunology, with advanced degrees and experience in developing bacterial vaccines, familiar with protein fusion techniques and vaccine delivery strategies

Obviousness Rationale

A PHOSITA would recognize that the PTD's disclosed variations represent predictable extensions of the source patent's core vaccine technology by applying known biotechnological techniques such as plant-based expression, nanocapsule delivery, and AI-assisted design to the existing PlcC-NetB fusion protein concept. The fundamental immunological approach remains consistent with the source patent, with the PTD merely introducing incremental technological improvements in protein production and delivery methods.

Obvious Combinations & Variations

Source Patent Element

PlcC-NetB fusion protein for preventing C. perfringens infection

PTD Variation

Plant-based expression system for producing the fusion protein

Obviousness Reasoning

Plant-based protein expression is a well-established technique in biotechnology, representing a predictable alternative to traditional bacterial or mammalian expression systems with known advantages in scalability and cost-effectiveness

Source Patent Element

Vaccine targeting C. perfringens in poultry

PTD Variation

Nanocapsule-based slow-release delivery system

Obviousness Reasoning

Controlled-release vaccine delivery is a standard approach in veterinary medicine, offering predictable improvements in vaccine efficacy and duration of protection through well-understood encapsulation technologies

Source Patent Element

Specific amino acid sequence for PlcC and NetB proteins

PTD Variation

AI-driven optimization of antigen combinations and adjuvants

Obviousness Reasoning

Computational methods for protein engineering and vaccine design are routine in biotechnology, representing a logical application of machine learning to refine existing protein-based vaccine strategies

Source Patent Element

Vaccine for preventing necrotic enteritis

PTD Variation

Wearable monitoring device with predictive machine learning algorithm

Obviousness Reasoning

Integrating health monitoring technologies with vaccine development is a foreseeable advancement, leveraging standard IoT and data analysis techniques to enhance veterinary healthcare interventions

Source Patent Element

Protein-based vaccine targeting specific bacterial pathogen

PTD Variation

High-throughput automated vaccine development platform

Obviousness Reasoning

Automated screening and development platforms are standard in biotechnology, representing an obvious method to accelerate and systematize vaccine research processes

35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the instant publication would have been obvious to a person having ordinary skill in the art at the time of invention, as they represent predictable technological extensions of US Patent 11857613, applying known biotechnological techniques to the foundational vaccine development approach for preventing C. perfringens infection in poultry, thereby rendering potential subsequent claims obvious and non-patentable.

Original Patent Information

Patent Number	US 11,857,613
Title	Vaccine for prevention of necrotic enteritis in poultry
Assignee(s)	Arizona Board of Regents on Behalf of Arizona State University